NEW YORK, September 13, 2018 /PRNewswire/ --
According to a report published by Progressive Markets, the cancer immunotherapy market was valued at USD 57.2 Billion in 2017 and is expected to reach USD 166.7 Billion by 2025 while
growing at a compound annual growth (CAGR) of 14.42%. The increasing spending on R&D activities for cancer immunotherapy,
growing occurrence of cancer and the rise in approvals for the clinical trials are the main drivers of the market. Additionally,
the number of people who have cancer is rising rapidly. According to a report released by the World's Health Organization's
International Agency for Research on Cancer, cancer is estimated to cause 9.6 Million deaths and have 18.1 Million new cases in
2018. Cancer immunotherapy is one of the treatment types for cancer and has gained widespread importance in recent years. Regen
BioPharma, Inc. (OTC: RGBP), Palatin Technologies, Inc. (NYSE: PTN), Agenus Inc. (NASDAQ: AGEN), BioLineRx Ltd. (NASDAQ:
BLRX), Ziopharm Oncology, Inc. (NASDAQ: ZIOP)
Based on application, the cancer immunotherapy market is divided into breast cancer, lung cancer, colorectal cancer, prostate
cancer, melanoma, head and neck cancer and others. The lung cancer and breast cancer segments are expected to have market size of
USD 22.3 Billion and USD 18.9 Billion respectively by 2025. Based on
end-user, the market is segmented into hospitals, cancer research centers, and clinics.
Regen BioPharma, Inc. (OTCQB: RGBP) earlier this week announced breaking news that it, "has identified
a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently-identified, novel
chemical compounds appear to inhibit NR2F6 and thus can potentially be developed for treating cancer.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint), which
may lead to developing therapies for treating cancers. Therapies that manipulate NR2F6 also show potential to act as cancer stem
cell differentiators, transforming cancer stem cells into normal cells.
The NR2F6 program at Regen aims to identify antagonists of NR2F6 in order to unleash the cancer-killing potential of a
patient's own immune system as well as identify agonists which should suppress the immune system in diseases where the immune
system is over-activated, such as autoimmunity.
'We have identified a handful of compounds, representing three different structural classes, that inhibit NR2F6 in our primary
screening assay,' says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. 'They exhibited a
dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Our next steps will focus on determining what effect they have on
human immune cells.'
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, 'This is exciting for
Regen to reach this point in its goal for developing therapies that treat cancer. These compounds should provide us the basis to
further refine our screening for successful antagonists in the development of immunologically-based cancer therapies. '
Correction: Regen BioPharma previously disclosed, in error, that 'inhibiting NR2F6 is believed to provide potential therapies
for treating autoimmunity.' The statement should read: Activating NR2F6 potentially leads to inhibiting the immune system and
should lead to therapies for treating autoimmunity diseases such as lupus."
Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide
therapeutics for the treatment of diseases and conditions with significant unmet medical need and commercial potential. The
Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted the bremelanotide New Drug Application
(NDA) for filing. The NDA was filed on March 23rd, 2018 by AMAG Pharmaceuticals, the
Company's exclusive North American licensee. Bremelanotide, an investigational melanocortin agonist, is being developed for the
treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. "We are very pleased with the FDA's acceptance of
the NDA filing for bremelanotide," said Carl Spana, Ph.D., Chief Executive Officer and President
of Palatin. "This is an important milestone for Palatin and reflects our drive and commitment to the development of novel
therapies to treat conditions with significant unmet medical need and commercial potential. We look forward to assisting AMAG
during the FDA review process. HSDD is an underserved medical condition and, if approved, bremelanotide has significant potential
as an as-desired treatment of HSDD in premenopausal women."
Agenus Inc. (NASDAQ: AGEN) is a clinical-stage immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. Recently, a study published in Cancer Cell reports on a novel
discovery made by Agenus Inc. that may enhance the immune activity of cancer-fighting antibodies, including those targeting
CTLA-4. Agenus has applied this discovery to its proprietary next-generation anti-CTLA-4 antibody (AGEN1181) on track for IND
filing in 2H2018. Specifically, the research team demonstrated that a change in the Fc region can significantly improve the
cross-talk between two immune cell types, such as antigen presenting cells (APCs) and T cells. This modification in the Fc region
increases the duration and strength of interaction between the immune cells. In cancer immunotherapy, such an interaction is
necessary to mount a potent immune response against cancer. "We have discovered a new mechanism involving a key portion of
antibodies that modulates biological function and cancer-fighting abilities," said Dr. Jeremy
Waight, Principal Scientist at Agenus and lead author of the study. "Based on our discovery, we can modify this region,
known as the Fc region, to significantly improve an antibody's biological activity, by improving its immunological activity.
We have already applied this discovery to our next generation anti-CTLA-4 antibody as well as other monospecific and
bispecific antibodies in our pre-clinical pipeline and observed dramatic improvement in immune responses and anti-tumor
activity."
BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company focused on oncology and immunology.
BioLineRx Ltd. recently announced positive results from the lead-in period of the GENESIS trial, a double-blind,
placebo-controlled Phase 3 trial comparing BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF), to G-CSF
alone, for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients.
"We are extremely encouraged by these results. Based on the robust data received from the first 11 patients, the DMC issued a
positive recommendation to stop the lead-in part of the study and move immediately to the randomized placebo-controlled part of
the study," stated Philip Serlin, Chief Executive Officer of BioLineRx. "This is the first Phase 3
trial for our lead BL-8040 program, and as such, it is an important milestone in BL-8040's comprehensive development plan. We
look forward to the top-line results from the randomized, double-blind, placebo-controlled part of the study, which are expected
in 2020."
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) is a Boston-based biotechnology company focused
on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer.
Ziopharm Oncology, Inc. recently announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients
with recurrent glioblastoma (rGBM). "We are excited about the first-ever dosing of this combination and its potential to bring a
potent and controlled anti-tumor immune response to glioblastoma," said Francois Lebel, M.D.,
Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. "By controlling interleukin 12,
Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of
checkpoints in this microenvironment. The combination with an anti-PD-1 has the potential to further improve anti-cancer effects
of IL-12 and provide a much-needed new therapeutic option for patients with brain cancer."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For regen biopharma, Inc. financial news dissemination and pr services,
FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be
either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination
thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on
or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments
for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site
or continue to post information about any companies the information contained herein is not intended to be used as the basis for
investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is
not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for
any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other
materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of
their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance,
and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com.
For further information:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com